Late Toxicities Burden in Patients with RAI-resistant Differentiate Thyroid Cancer (DTC) on Therapy with Lenvatinib
Thyroid World Congress ePoster Library. Platini F. 06/20/19; 272061; 203
Dr. Francesca Platini
Dr. Francesca Platini
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)

Background: Lenvatinib is approved for patients with RAI-resistant DTC. Whether the rate and the timing of acute toxicities is very well known, the definition and the burden of late toxicities have to be clarified yet.

Methods: We reviewed data from January 2015 to December 2018 on RAI-resistant DTC patients. Median duration of lenvatinib from SELECT trial was 13.8 months and accordingly we selected as late toxicities only those appeared after at least one year of lenvatinib treatment. AEs were described according to CTCAE 4.0.

Results: 72 RAI-resistant DTC patients on TKIs were evaluated and, among them, 25 were treated with lenvatinib. Female/Male 17/8, with a median age of 65 years (43-84). The median time of treatment duration was 12 months (12-44). The median time to develop any AEs was 1 month. The most common were G2 hypertension in 13/25 patients (52%) with G3 in 7/13; G1 diarrhea in 7/25 patients (28%) with G2 in 4/7 patients and G2 fatigue in 4/25 patients (16%). After 12 months of treatment, all patients had at least one dose reduction. New and late hypertension occurred in 7/25 pts, cardiovascular toxicities in 6/25 (QTc prolongation 2/5, q-wave 1/5), proteinuria in 3/25 and fatigue in 2/25. All toxicities were G2. Prolonged diarrhea G1 was observed in 7/25 patients.

Conclusions: The late toxicities burden of patients on lenvatinib was 72%. Cardiovascular (52%) and proteinuria (12%) were the most common late toxicities. A continuing active monitoring of side effects is mandatory even after prolonged lenvatinib exposure.


Background: Lenvatinib is approved for patients with RAI-resistant DTC. Whether the rate and the timing of acute toxicities is very well known, the definition and the burden of late toxicities have to be clarified yet.

Methods: We reviewed data from January 2015 to December 2018 on RAI-resistant DTC patients. Median duration of lenvatinib from SELECT trial was 13.8 months and accordingly we selected as late toxicities only those appeared after at least one year of lenvatinib treatment. AEs were described according to CTCAE 4.0.

Results: 72 RAI-resistant DTC patients on TKIs were evaluated and, among them, 25 were treated with lenvatinib. Female/Male 17/8, with a median age of 65 years (43-84). The median time of treatment duration was 12 months (12-44). The median time to develop any AEs was 1 month. The most common were G2 hypertension in 13/25 patients (52%) with G3 in 7/13; G1 diarrhea in 7/25 patients (28%) with G2 in 4/7 patients and G2 fatigue in 4/25 patients (16%). After 12 months of treatment, all patients had at least one dose reduction. New and late hypertension occurred in 7/25 pts, cardiovascular toxicities in 6/25 (QTc prolongation 2/5, q-wave 1/5), proteinuria in 3/25 and fatigue in 2/25. All toxicities were G2. Prolonged diarrhea G1 was observed in 7/25 patients.

Conclusions: The late toxicities burden of patients on lenvatinib was 72%. Cardiovascular (52%) and proteinuria (12%) were the most common late toxicities. A continuing active monitoring of side effects is mandatory even after prolonged lenvatinib exposure.


    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings